ATE251636T1 - O-glycaninhibitoren von selectinvermittelten entzüngen - Google Patents

O-glycaninhibitoren von selectinvermittelten entzüngen

Info

Publication number
ATE251636T1
ATE251636T1 AT96928073T AT96928073T ATE251636T1 AT E251636 T1 ATE251636 T1 AT E251636T1 AT 96928073 T AT96928073 T AT 96928073T AT 96928073 T AT96928073 T AT 96928073T AT E251636 T1 ATE251636 T1 AT E251636T1
Authority
AT
Austria
Prior art keywords
glycans
selectin
glycan
beta
disialylated
Prior art date
Application number
AT96928073T
Other languages
German (de)
English (en)
Inventor
Rodger P Mcever
Richard D Cummings
Kevin L Moore
Original Assignee
Univ Oklahoma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oklahoma filed Critical Univ Oklahoma
Application granted granted Critical
Publication of ATE251636T1 publication Critical patent/ATE251636T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596Molecules with a "CD"-designation not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT96928073T 1995-08-03 1996-08-02 O-glycaninhibitoren von selectinvermittelten entzüngen ATE251636T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US51092095A 1995-08-03 1995-08-03
US1779496P 1996-05-15 1996-05-15
US64980296A 1996-05-17 1996-05-17
PCT/US1996/012820 WO1997006176A2 (en) 1995-08-03 1996-08-02 Peptide and o-glycan inhibitors of selectin mediated inflammation

Publications (1)

Publication Number Publication Date
ATE251636T1 true ATE251636T1 (de) 2003-10-15

Family

ID=27360885

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96928073T ATE251636T1 (de) 1995-08-03 1996-08-02 O-glycaninhibitoren von selectinvermittelten entzüngen

Country Status (11)

Country Link
EP (1) EP0850243B1 (enExample)
JP (1) JPH11510543A (enExample)
KR (1) KR100523506B1 (enExample)
AT (1) ATE251636T1 (enExample)
AU (1) AU723262B2 (enExample)
CA (1) CA2228512A1 (enExample)
DE (1) DE69630307T2 (enExample)
DK (1) DK0850243T3 (enExample)
ES (1) ES2208759T3 (enExample)
MX (1) MXPA98000968A (enExample)
WO (1) WO1997006176A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277975B1 (en) 1992-10-23 2001-08-21 Genetics Institute, Inc. Fusions of P-selectin ligand protein and polynucleotides encoding same
US7223845B2 (en) 1998-06-16 2007-05-29 The Board Of Regents Of The University Of Oklahoma Synthetic glycosulfopeptides and methods of synthesis thereof
US20030143662A1 (en) 1998-06-16 2003-07-31 Cummings Richard D. Glycosulfopeptide inhibitors of leukocyte rolling and methods of use thereof
AU773542B2 (en) 1998-06-16 2004-05-27 Board Of Regents Of The University Of Oklahoma, The Glycosulfopeptides and methods of synthesis and use thereof
NZ528610A (en) * 1998-10-30 2005-03-24 Inst Genetics Llc Inhibition of differentiation of cytotoxic T-cells by P-selectin ligand (PSGL) antagonists
EP1131334A4 (en) * 1998-11-21 2003-05-21 Univ California Use of core 2 glcnac transferase inhibitors in treating inflammation
US6492152B1 (en) 1999-06-15 2002-12-10 The Board Of Regents Of The University Of Oklahoma Core 1 β3-galactosyl transferases and methods of use thereof
US7256171B1 (en) 1999-11-20 2007-08-14 The Regents Of The University Of California Use of core 2 G1cNAc transferase inhibitors in treating inflammation
AU2000274809A1 (en) * 2000-09-12 2002-03-26 Genetics Institute Llc Inhibition of stenosis or restenosis by p-selectin antagonists
JP2005503756A (ja) * 2000-12-29 2005-02-10 サビエント ファーマシューティカルズ,インコーポレイティド 硫酸化部分を含むエピトープを含む単離分子、当該エピトープに対する抗体、及びその使用
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
AU2003255337A1 (en) * 2002-07-31 2004-02-23 Kylix B.V. Use of genes identified to be involved in tumor development for the development of anti-cancer drugs
JP4599027B2 (ja) * 2002-10-30 2010-12-15 東洋水産株式会社 L−セレクチン結合阻害剤
FI20021989A0 (fi) * 2002-11-06 2002-11-06 Halina Miller-Podraza Korkean affiniteetin Helicobacter pylori-reseptorit ja niiden käyttö
US20080182801A1 (en) 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
GB0513881D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
GB0329667D0 (en) 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
UY28886A1 (es) 2004-05-10 2005-12-30 Boehringer Ingelheim Int Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
BRPI0510561A (pt) 2004-05-11 2007-11-20 Abgenomics Corp epìtopos que induzem morte de célula t
GB0513883D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Diagnosis of Atherosclerosis
GB0513888D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
WO2007067983A2 (en) * 2005-12-09 2007-06-14 Wyeth Sulfotyrosine specific antibodies and uses therefor
JP5331293B2 (ja) * 2006-04-28 2013-10-30 公益財団法人野口研究所 多様性を表現するオリゴ糖またはその誘導体
RU2520105C2 (ru) * 2008-09-02 2014-06-20 Констракшн Рисёрч Энд Текнолоджи Гмбх Содержащая пластифицирующую добавку композиция добавки-ускорителя твердения
EP2494980A3 (en) * 2009-10-21 2013-03-13 ETH Zurich Medical utility of glycans
CN116063522A (zh) 2011-06-13 2023-05-05 美国全心医药生技股份有限公司 抗psgl-1抗体及其用途
JP7244422B2 (ja) 2017-01-11 2023-03-22 ブリストル-マイヤーズ スクイブ カンパニー Psgl-1アンタゴニスト及びその使用
SG11201907848YA (en) 2017-03-14 2019-09-27 Five Prime Therapeutics Inc Antibodies binding to vista at acidic ph
MX2020009786A (es) 2018-03-21 2020-10-12 Five Prime Therapeutics Inc Anticuerpos de union a supresor de la activacion de celulas t que contiene el dominio variable de inmunoglobulina (vista) a ph acido.
US12091462B2 (en) 2018-07-11 2024-09-17 Five Prime Therapeutics, Inc. Antibodies binding to vista at acidic pH

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0668907A1 (en) * 1992-11-16 1995-08-30 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for p-selectin and methods of use thereof
AU2361395A (en) * 1994-04-28 1995-11-29 Genetics Institute Inc. Novel P-selectin ligand protein

Also Published As

Publication number Publication date
KR20040039440A (ko) 2004-05-10
EP0850243B1 (en) 2003-10-08
CA2228512A1 (en) 1997-02-20
AU723262B2 (en) 2000-08-24
DE69630307D1 (de) 2003-11-13
WO1997006176A2 (en) 1997-02-20
DE69630307T2 (de) 2004-07-15
MXPA98000968A (es) 2002-07-15
ES2208759T3 (es) 2004-06-16
AU6766996A (en) 1997-03-05
EP0850243A2 (en) 1998-07-01
WO1997006176A3 (en) 1997-07-24
JPH11510543A (ja) 1999-09-14
DK0850243T3 (da) 2004-02-02
KR100523506B1 (en) 2005-10-24

Similar Documents

Publication Publication Date Title
ATE251636T1 (de) O-glycaninhibitoren von selectinvermittelten entzüngen
Kenne et al. Structural studies of Shigella flexneri O‐antigens
Vieira et al. Structure of a fucose-branched chondroitin sulfate from sea cucumber. Evidence for the presence of 3-O-sulfo-beta-D-glucuronosyl residues
Lamblin et al. Primary structure determination of five sialylated oligosaccharides derived from bronchial mucus glycoproteins of patients suffering from cystic fibrosis. The occurrence of the NeuAc alpha (2----3) Gal beta (1----4)[Fuc alpha (1----3)] GlcNAc beta (1----.) structural element revealed by 500-MHz 1H NMR spectroscopy.
Capek et al. An acetylated galactoglucomannan from Picea abies L. Karst
McConville et al. The glycoinositolphospholipid profiles of two Leishmania major strains that differ in lipophosphoglycan expression
CA2261597A1 (fr) Polysaccharides synthetiques, procede pour leur preparation et compositions pharmaceutiques les contenant
ID29945A (id) Campuran-campuran karbohidrat
CA2110386A1 (en) Method for the Enzymatic Synthesis of Alpha-Sialylated Oligosaccharide Glycosides
Serafini-Cessi et al. Guinea-pig kidney β-N-acetylgalactosaminyltransferase towards Tamm-Horsfall glycoprotein. Requirement of sialic acid in the acceptor for transferase activity
IL86881A0 (en) Polysaccharides extractred from plants,their preparation and pharmaceutical compositions containing them
Linsley et al. Applications of electrospray mass spectrometry to erythropoietin N-and O-linked glycans
Wieruszeski et al. Structure of two new oligosaccharides isolated from human milk: sialylated lacto-N-fucopentaoses I and II
ATE41785T1 (de) Membranoese polysaccharide, verwendbar insbesondere als arzneimittel und verfahren zu ihrer herstellung.
da Silva et al. Carbohydrate, glycopeptide and protein components of the lichen Sticta sp. and effect of storage
Nergard et al. Structure-immunomodulating activity relationships of a pectic arabinogalactan from Vernonia kotschyana Sch. Bip. ex Walp.
Tsuji et al. The carbohydrate moiety of Band-3 glycoprotein of human erythrocyte membranes
Degroote et al. Sulfated oligosaccharides isolated from the respiratory mucins of a secretor patient suffering from chronic bronchitis
Omarsdottir et al. Structural characterisation of novel lichen heteroglycans by NMR spectroscopy and methylation analysis
Kitajima et al. Analytical methods for identifying and quantitating deamidated sialic acid (2-keto-3-deoxy-d-glycero-d-galactonononic acid) and α2→ 8-linked poly (oligo) nonulosonate residues in glycoconjugates
WO1997021416A3 (es) Glicoconjugados de substancias opiaceas
Ansari et al. Structural studies of the O-antigen from Vibrio cholerae O: 21
Tyler et al. Specific capsular polysaccharide of type VII Pneumococcus
Rahman et al. The structure of the capsular polysaccharide from a swarming strain of pathogenic Proteus vulgaris
Palatnik et al. Partial chemical characterization of the carbohydrate moieties in Leishmania adleri glycoconjugates

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0850243

Country of ref document: EP

REN Ceased due to non-payment of the annual fee